Cancer Prevention to price 1,923,076 shares between $12.00 and $14.00

Aegis and Maxim help fund clinical trials, research and development

By Devika Patel

Knoxville, Tenn., Feb. 3 – Cancer Prevention Pharmaceuticals, Inc. will sell 1,923,076 common shares in its initial public offering with a 45-day greenshoe option of 288,462 additional shares, according to a Form S-1/A filed Friday with the Securities and Exchange Commission. The company has registered up to $28.75 million of stock for the deal, which was announced on Dec. 23.

The shares will be sold at a price expected to fall between $12.00 and $14.00 per share.

Aegis Capital Corp. and Maxim Group LLC are the bookrunners.

Proceeds would be used for clinical trials, research and development, working capital and other general corporate purposes.

The biopharmaceutical company is based in Tucson, Ariz. It expects its stock to be listed on the New York Stock Exchange under the symbol “CPP.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.